Abstract 4679: Molecular pathology and BTKi pharmacology of DLBCL-PDXs
Jingjing Wang,Yueying Wang,Wubin Qian,Jia Xue,Sheng Guo,Likun Zhang,Henry Qixiang Li
DOI: https://doi.org/10.1158/1538-7445.am2023-4679
IF: 11.2
2023-04-04
Cancer Research
Abstract:Abstract Diffuse large B-cell lymphoma (DLBCL), the largest subtype of non-Hodgkin’s lymphoma (NHL, ~40%), is a heterogeneous disease with diverse pathogenesis, represented by different subtypes/genotypes based on lymphoma related specific gene expression profiling according to cell-of-origin (COO) and/or mutation profiles, likely influencing their responses to drug treatment. Patient derived xenografts (PDXs) represent powerful experimental system to investigate heterogeneous molecular pathology, and their corresponding pharmacology of DLBCLs. We created a unique cohort of 19 PDXs representative of diverse subtypes of de novo DLBCL patients, along with 15 EBV transformed DLBCLs during xenografting, followed by comprehensive molecular pathological analysis, using “EBV scan”, COO and LymphGen algorithm. The 19 de novo DLBCL-PDXs were classified into activated B cell-like (7/19 ABC, including 2 EBV+), germinal center B-cell-like (4/19 GCB) and unclassified (8/19 including 4 EBV+); the 15 EBV transformed DLBCL include two ABC, one GCB and 12 unclassified. The de novo DLBCL-PDXs were also annotated as MCD, BN2, N1, A53, ST2, and unknown genotypes. Clustering and principal component analysis (PCA) clearly separated EBV+ DLBCL-PDXs (regardless of de novo DLBCL, EBV-associated, or EBV transformed DLBCLs) from the EBV− de novo DLBCL-PDXs, suggesting distinct molecular pathogenesis, while no apparent difference between the two EBV+ DLBCLs suggested the similar pathogenesis. The expanded mouse clinical trial of BTKi using drinking water administration of ibrutinib (0.16mg/ml) showed: 1) EBV− MCD and BN2 genotype are largely sensitive, suggesting these models’ dependency of chronic BCR signaling; 2) all EBV+ DLBCLs, regardless of the origin or genotypes, are all insensitive; 3) there are some cases of EBV− non-MCD/BN2 models being sensitive, likely due to the presence of certain related activating mutations. Molecular pathology analysis also demonstrated EBV+ PDXs, including significantly elevated BCL2 and down-regulated BCL6, in contrast to EBV− DLBCL-PDXs, implicating possible sensitivity to respective treatments. In summary, these observations in PDXs, some of which are consistent with the retrospective analysis of clinical trials, can be used to help develop BTKi and other treatment for DLBCLs. Citation Format: Jingjing Wang, Yueying Wang, Wubin Qian, Jia Xue, Sheng Guo, Likun Zhang, Henry Qixiang Li. Molecular pathology and BTKi pharmacology of DLBCL-PDXs. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4679.
oncology